Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metabolism of [14C]Lorlatinib in Healthy Male Volunteers
NCT03184168Phase 1Completed
- Sponsor
- Pfizer
- Start
- Jul 2017
- Primary completion
- Aug 2017
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of lorlatinib in non-small cell lung cancer (NSCLC), sponsored by Pfizer. Primary endpoint: Metabolic profiling for lorlatinib at 14 days. Started Jul 2017; status: completed.
02
Drugs
lorlatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03184168.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03184168.